Ignite Creation Date:
2025-12-24 @ 7:08 PM
Ignite Modification Date:
2026-01-01 @ 7:11 PM
Study NCT ID:
NCT06324357
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2024-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'C562730', 'term': 'Adenocarcinoma Of Esophagus'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000614160', 'term': 'trastuzumab deruxtecan'}, {'id': 'D000080044', 'term': 'Ado-Trastuzumab Emtansine'}, {'id': 'D000068878', 'term': 'Trastuzumab'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'C000726995', 'term': 'zanidatamab'}], 'ancestors': [{'id': 'D008453', 'term': 'Maytansine'}, {'id': 'D018942', 'term': 'Macrolides'}, {'id': 'D007783', 'term': 'Lactones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D047029', 'term': 'Lactams, Macrocyclic'}, {'id': 'D047028', 'term': 'Macrocyclic Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 768}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-06-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2029-01-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-19', 'studyFirstSubmitDate': '2024-03-15', 'studyFirstSubmitQcDate': '2024-03-15', 'lastUpdatePostDateStruct': {'date': '2025-12-22', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-03-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-01-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period', 'timeFrame': 'up to 21 days', 'description': 'The MTD evaluation period is defined as the first 21 days of the first treatment cycle for Cohorts A, B, C, G, K, and O. The MTD evaluation period is defined as the first 28 days after the first administration of any trial medication for Cohorts M and N.'}, {'measure': 'Dose optimization and justification (Phase II): Objective response (OR)', 'timeFrame': 'up to 50 months', 'description': 'Objective response (OR) is defined as the best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, or treatment discontinuation as assessed by investigator review.'}], 'secondaryOutcomes': [{'measure': 'Dose escalation (Phase Ib): Objective response (OR)', 'timeFrame': 'up to 50 months'}, {'measure': 'Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) during the entire treatment period', 'timeFrame': 'up to 50 months'}, {'measure': 'Dose escalation (Phase Ib): Maximum measured concentration of zongertinib (at steady state) (Cmax,(ss))', 'timeFrame': 'up to 2 days', 'description': 'For cycle 2 only.'}, {'measure': 'Dose escalation (Phase Ib): Area under the concentration-time curve of zongertinib over the time interval from 0 to 4h at steady state (AUC0-4h,ss)', 'timeFrame': 'up to 2 days', 'description': 'For cycle 2 only.'}, {'measure': 'Dose escalation (Phase Ib): Area under the concentration-time curve of zongertinib over the time interval from 0 to the last quantifiable data point at steady state (AUC0-tz,ss)', 'timeFrame': 'up to 2 days', 'description': 'For cycle 2 only.'}, {'measure': 'Dose optimization and justification (Phase II): Progression-free survival (PFS)', 'timeFrame': 'up to 50 months', 'description': 'PFS is defined as the time from treatment start until the earliest date of tumor progression according RECIST 1.1 based on investigator review or death from any cause, whichever occurs first.'}, {'measure': 'Dose optimization and justification (Phase II): Disease control (DC)', 'timeFrame': 'up to 50 months', 'description': 'DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST 1.1 from first treatment administration until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, or treatment discontinuation, as assessed by investigator review.'}, {'measure': 'Dose optimization and justification (Phase II): Occurrence of treatment-emergent AEs leading to zongertinib (BI 1810631) dose reduction during the on-treatment period', 'timeFrame': 'up to 50 months'}, {'measure': 'Dose optimization and justification (Phase II): Maximum measured concentration (at steady state) (Cmax,(ss))', 'timeFrame': 'up to 50 months'}, {'measure': 'Dose optimization and justification (Phase II): Area under the concentration-time curve over the time interval from 0 to the last quantifiable data point at steady state (AUC0-tz,ss)', 'timeFrame': 'up to 50 months'}, {'measure': 'Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - PRO-CTCAE', 'timeFrame': 'up to 24 weeks', 'description': 'The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library was developed to elicit symptomatic toxicity information directly from patients in cancer clinical trials. The items selected for this trial are: Mouth/throat sores, Taste changes, Decreased appetite, Nausea, Vomiting, Constipation, Diarrhoea, Shortness of breath, Cough, Rash, Skin dryness, Hair loss, Itching, Numbness \\& Tingling, Fatigue, Nosebleed, Headache.\n\nPRO-CTCAE responses are scored from 0 (=none) to 4 (=very severe) (or 0/1 for absent/present).'}, {'measure': 'Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - EORTC IL46', 'timeFrame': 'up to 48 weeks', 'description': 'The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".'}, {'measure': 'Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - EORTC IL19', 'timeFrame': 'up to 48 weeks', 'description': 'The EORTC IL19 consists of five physical functioning scale items. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Metastatic Breast Cancer', 'Metastatic Gastric Adenocarcinoma', 'Gastroesophageal Junction Adenocarcinoma', 'Esophageal Adenocarcinoma', 'Colorectal Cancer']}, 'referencesModule': {'references': [{'pmid': '41108088', 'type': 'DERIVED', 'citation': 'Hurvitz S, Simonelli M, Yarza R, Berz D, Kitano S, Del Conte G, Acosta Eyzaguirre D, Doger de Speville Uribe BG, Maier D, Erzen D, Aykut Yazgili S, Curigliano G, Deng T, Yan M, Zhang Q, Wang X, Nakayama I, Shitara K. Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Future Oncol. 2025 Nov;21(26):3385-3393. doi: 10.1080/14796694.2025.2569553. Epub 2025 Oct 17.'}], 'seeAlsoLinks': [{'url': 'https://www.mystudywindow.com', 'label': 'Related Info'}, {'url': 'https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.TPS509', 'label': 'Related Info'}, {'url': 'https://www.esmoopen.com/article/S2059-7029(25)00849-X/fulltext#:~:text=Beamion%20BCGC-1%20%28NCT06324357%29%20is%20a%20Ph%20Ib%2FII%20trial,to%20ASCO-CAP%20guidelines%29%2C%20pretreated%20mBC%20will%20be%20enrolled.', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': "This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow.\n\nIn this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group.\n\nDuring the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the informed consent form (ICF)\n* Cohorts A to K and Cohort O: Documented Human epidermal growth factor receptor 2 overexpressing and/or amplified (HER2+), metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mGEAC).\n* Cohorts L (L-ext), M, and N (metastatic colorectal cancer (mCRC)): Documented Human epidermal growth factor receptor 2 (HER2) overexpression/amplification according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) gastric cancer guidelines and according to the result of local testing.\n* For dose optimization and justification (Phase II): Patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue\n* History of prior treatment lines in palliative setting:\n\n * For cohorts A, B, C, D, E, F, G, H, I, I-ext, J, J-ext, K and O documented investigator assessed progression after HER2-directed treatment for unresectable locally advanced or metastatic disease (For Cohorts D, H, I (I-ext), J (J-ext) - patients must have been pretreated with trastuzumab deruxtecan (T-DXd) and have progressed or have been intolerant to previous T-DXd).\n * For cohorts L, L-ext, M and N documented progression or recurrence of disease during or following their latest line of therapy. Patients must have had at least one prior line of therapy for locally advanced unresectable disease or metastatic disease (adjuvant and neoadjuvant therapy excluded) and documented disease progression or recurrence of disease during or following their latest line of therapy. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival.\n* Presence of at least one measurable lesion according to RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n* Adequate organ function based on laboratory values Further inclusion criteria apply.\n\nExclusion criteria:\n\n* Previous treatment with:\n\n * Any small molecule HER2 inhibitor in the palliative setting in Cohorts D, E, F, H, L, L-ext, M, and N. In Cohort D allowed in up to 15 patients in each dose level (DL).\n * T-DXd in Cohorts E and F. In Cohort E allowed in up to 15 patients in each DL.\n * trastuzumab emtansine (T-DM1) in the palliative setting in Cohort D and H. In Cohort H allowed in up to 15 patients in each DL.\n * Capecitabine in Cohort D and H. In Cohort D allowed in up to 15 patients in each DL\n* Presence of uncontrolled and/or symptomatic brain metastases, or leptomeningeal disease\n* Mean resting corrected QT interval (QT interval corrected for heart rate by Fridericia´s formula (QTcF)) \\>470 msec.\n* Any factors that increase the risk of QT interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, personal or family history of long QT syndrome or unexplained sudden death under 40 years-of-age.\n* Ejection fraction \\<50% or the lower limit of normal of the institutional standard within 28 days prior to randomization\n* History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening Further exclusion criteria apply.'}, 'identificationModule': {'nctId': 'NCT06324357', 'briefTitle': 'Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)', 'orgStudyIdInfo': {'id': '1479-0012'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab emtansine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab deruxtecan']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab deruxtecan']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort D: zongertinib + Trastuzumab emtansine', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab emtansine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab deruxtecan']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab deruxtecan']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort G: zongertinib + trastuzumab + capecitabine', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab', 'Drug: Capecitabine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort K: zongertinib + trastuzumab', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort H: zongertinib + trastuzumab + capecitabine', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab', 'Drug: Capecitabine']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort I: zongertinib', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort J: zongertinib + trastuzumab', 'description': 'Dose optimization (Phase II).', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort I-ext: zongertinib', 'description': 'Extension Phase II', 'interventionNames': ['Drug: Zongertinib']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort J-ext: zongertinib + trastuzumab', 'description': 'Extension Phase II', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort M: zongertinib + mFOLFOX6', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: mFOLFOX6']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort N: zongertinib + trastuzumab + mFOLFOX6', 'description': 'Dose escalation (Phase Ib)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab', 'Drug: mFOLFOX6']}, {'type': 'EXPERIMENTAL', 'label': 'Phase Ib - Cohort O: zongertinib + zanidatamab', 'description': 'Dose escalation (Phase Ib) - is not conducted in China or South Korea', 'interventionNames': ['Drug: Zongertinib', 'Drug: zanidatamab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort L: zongertinib + trastuzumab', 'description': 'Dose justification (Phase II)', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab']}, {'type': 'EXPERIMENTAL', 'label': 'Phase II - Cohort L-ext: zongertinib + trastuzumab', 'description': 'Extension Phase II', 'interventionNames': ['Drug: Zongertinib', 'Drug: Trastuzumab']}], 'interventions': [{'name': 'Zongertinib', 'type': 'DRUG', 'otherNames': ['BI 1810631, Hernexeos®'], 'description': 'Zongertinib', 'armGroupLabels': ['Phase II - Cohort D: zongertinib + Trastuzumab emtansine', 'Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan', 'Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan', 'Phase II - Cohort H: zongertinib + trastuzumab + capecitabine', 'Phase II - Cohort I-ext: zongertinib', 'Phase II - Cohort I: zongertinib', 'Phase II - Cohort J-ext: zongertinib + trastuzumab', 'Phase II - Cohort J: zongertinib + trastuzumab', 'Phase II - Cohort L-ext: zongertinib + trastuzumab', 'Phase II - Cohort L: zongertinib + trastuzumab', 'Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine', 'Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan', 'Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan', 'Phase Ib - Cohort G: zongertinib + trastuzumab + capecitabine', 'Phase Ib - Cohort K: zongertinib + trastuzumab', 'Phase Ib - Cohort M: zongertinib + mFOLFOX6', 'Phase Ib - Cohort N: zongertinib + trastuzumab + mFOLFOX6', 'Phase Ib - Cohort O: zongertinib + zanidatamab']}, {'name': 'Trastuzumab deruxtecan', 'type': 'DRUG', 'otherNames': ['T-DXd; Enhertu®'], 'description': 'Trastuzumab deruxtecan', 'armGroupLabels': ['Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan', 'Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan', 'Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan', 'Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan']}, {'name': 'Trastuzumab emtansine', 'type': 'DRUG', 'otherNames': ['T-DM1; Kadcyla®'], 'description': 'Trastuzumab emtansine', 'armGroupLabels': ['Phase II - Cohort D: zongertinib + Trastuzumab emtansine', 'Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine']}, {'name': 'Trastuzumab', 'type': 'DRUG', 'description': 'Herceptin®', 'armGroupLabels': ['Phase II - Cohort H: zongertinib + trastuzumab + capecitabine', 'Phase II - Cohort J-ext: zongertinib + trastuzumab', 'Phase II - Cohort J: zongertinib + trastuzumab', 'Phase II - Cohort L-ext: zongertinib + trastuzumab', 'Phase II - Cohort L: zongertinib + trastuzumab', 'Phase Ib - Cohort G: zongertinib + trastuzumab + capecitabine', 'Phase Ib - Cohort K: zongertinib + trastuzumab', 'Phase Ib - Cohort N: zongertinib + trastuzumab + mFOLFOX6']}, {'name': 'Capecitabine', 'type': 'DRUG', 'description': 'Xeloda®', 'armGroupLabels': ['Phase II - Cohort H: zongertinib + trastuzumab + capecitabine', 'Phase Ib - Cohort G: zongertinib + trastuzumab + capecitabine']}, {'name': 'mFOLFOX6', 'type': 'DRUG', 'description': 'mFOLFOX6', 'armGroupLabels': ['Phase Ib - Cohort M: zongertinib + mFOLFOX6', 'Phase Ib - Cohort N: zongertinib + trastuzumab + mFOLFOX6']}, {'name': 'zanidatamab', 'type': 'DRUG', 'description': 'zanidatamab', 'armGroupLabels': ['Phase Ib - Cohort O: zongertinib + zanidatamab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85054', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Mayo Clinic-Arizona', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '90703', 'city': 'Cerritos', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'The Oncology Institute of Hope and Innovation', 'geoPoint': {'lat': 33.85835, 'lon': -118.06479}}, {'zip': '90064', 'city': 'Los Angeles', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Ellison Medical Institute', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90067', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Valkyrie Clinical Trials', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'University of California Los Angeles', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'University of California Irvine', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Sharp Memorial Hospital', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Yale University School of Medicine', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Mayo Clinic - Florida', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'H. Lee Moffitt Cancer Center and Research Institute', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '46250', 'city': 'Indianapolis', 'state': 'Indiana', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Community Health Network', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'University of Iowa Hospitals and Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Mayo Clinic, Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Memorial Sloan-Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '17033', 'city': 'Hershey', 'state': 'Pennsylvania', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Penn State Milton S. Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '57105', 'city': 'Sioux Falls', 'state': 'South Dakota', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Avera Cancer Institute', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '38120', 'city': 'Memphis', 'state': 'Tennessee', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Baptist Cancer Center - Memphis', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'SCRI Oncology Partners', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Tennessee Oncology, Pllc', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'The Methodist Hospital Research Institute', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Inova Schar Cancer Institute', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Virginia Cancer Specialists, PC', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedstates@bitrialsupport.com', 'phone': '833-602-2368'}], 'facility': 'Fred Hutchinson Cancer Research Center', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '1200', 'city': 'Brussels', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'belgique@bitrialsupport.com', 'phone': '080049616'}], 'facility': 'Cliniques Universitaires Saint-Luc', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '2650', 'city': 'Edegem', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'belgique@bitrialsupport.com', 'phone': '080049616'}], 'facility': 'Edegem - UNIV UZ Antwerpen', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': '3000', 'city': 'Leuven', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'belgique@bitrialsupport.com', 'phone': '080049616'}], 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '6800', 'city': 'Libramont-Chevigny', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'belgique@bitrialsupport.com', 'phone': '080049616'}], 'facility': 'Hôpital Vivalia De Libramont'}, {'zip': '4000', 'city': 'Liège', 'status': 'TERMINATED', 'country': 'Belgium', 'facility': 'Centre Hospitalier Universitaire de Liège', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '5000', 'city': 'Namur', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'belgique@bitrialsupport.com', 'phone': '080049616'}], 'facility': 'CHU UCL Namur', 'geoPoint': {'lat': 50.4669, 'lon': 4.86746}}, {'zip': '130012', 'city': 'Changchun', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Jilin Province Cancer Hospital', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '130021', 'city': 'Changchun', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '310000', 'city': 'Hangzhou', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '150081', 'city': 'Harbin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Harbin Medical University Cancer Hospital', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '210029', 'city': 'Nanjing', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Jiangsu Province Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '200032', 'city': 'Shanghai', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '300060', 'city': 'Tianjin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Tianjin Cancer Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '450003', 'city': 'Zhengzhou', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'china@bitrialsupport.com', 'phone': '4001200553'}], 'facility': 'Henan Cancer Hospital', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '33076', 'city': 'Bordeaux', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'INS Bergonie', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '14076', 'city': 'Caen', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'CTR François Baclesse', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '21000', 'city': 'Dijon', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'CTR Georges-François Leclerc', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '69008', 'city': 'Lyon', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'CTR Leon Berard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '13273', 'city': 'Marseille', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'INS Paoli-Calmettes', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '75020', 'city': 'Paris', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'HOP Tenon', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '35042', 'city': 'Rennes', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'CTR Eugène Marquis', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '44800', 'city': 'Saint-Herblain', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': "Institut de Cancérologie de l'Ouest", 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'zip': '67200', 'city': 'Strasbourg', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'Institut de Cancérologie de Strasbourg', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '31059', 'city': 'Toulouse', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'INS Claudius Regaud IUCT-Oncopole', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '94800', 'city': 'Villejuif', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'france@bitrialsupport.com', 'phone': '0805102354'}], 'facility': 'INS Gustave Roussy', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '01307', 'city': 'Dresden', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Universitätsklinikum Carl Gustav Carus Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '91054', 'city': 'Erlangen', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Universitätsklinikum Erlangen', 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'zip': '45136', 'city': 'Essen', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Evang. Kliniken Essen-Mitte gGmbh', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '22763', 'city': 'Hamburg', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Asklepios Kliniken GmbH & Co. KGaA', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '68167', 'city': 'Mannheim', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Universitätsklinikum Mannheim GmbH', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'zip': '89075', 'city': 'Ulm', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'deutschland@bitrialsupport.com', 'phone': '08007234742'}], 'facility': 'Universitätsklinikum Ulm', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '10060', 'city': 'Candiolo (TO)', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Istituto Di Candiolo', 'geoPoint': {'lat': 44.95858, 'lon': 7.59812}}, {'zip': '71122', 'city': 'Foggia', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Az.Osp. Universitaria "Ospedali Riuniti"', 'geoPoint': {'lat': 41.45845, 'lon': 15.55188}}, {'zip': '47014', 'city': 'Meldola (FC)', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Istituto Scientifico Romagnolo', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'zip': '20132', 'city': 'Milan', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Ospedale San Raffaele S.r.l.', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20141', 'city': 'Milan', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Istituto Europeo di Oncologia', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '95045', 'city': 'Misterbianco (CT)', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Humanitas Istituto Clinico Catanese S.p.A.', 'geoPoint': {'lat': 37.51803, 'lon': 15.00913}}, {'zip': '80131', 'city': 'Napoli', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Istituto Nazionale IRCCS Tumori Fondazione Pascale', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '20089', 'city': 'Rozzano', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'italia@bitrialsupport.com', 'phone': '800977373'}], 'facility': 'Istituto Clinico Humanitas', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '464-8681', 'city': 'Aichi, Nagoya', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Aichi Cancer Center Hospital'}, {'zip': '259-1193', 'city': 'Isehara', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Tokai University Hospital', 'geoPoint': {'lat': 35.39932, 'lon': 139.31019}}, {'zip': '892-0833', 'city': 'Kagoshima', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Hakuaikai Sagara Hospital', 'geoPoint': {'lat': 31.56667, 'lon': 130.55}}, {'zip': '241-8515', 'city': 'Kanagawa, Yokohama', 'status': 'RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Kanagawa Cancer Center'}, {'zip': '277-8577', 'city': 'Kashiwa-shi', 'status': 'RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'National Cancer Center Hospital East'}, {'zip': '606-8507', 'city': 'Kyoto, Kyoto', 'status': 'RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Kyoto University Hospital'}, {'zip': '541-8567', 'city': 'Osaka', 'status': 'RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Osaka International Cancer Institute', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '135-8550', 'city': 'Tokyo, Koto-ku', 'status': 'RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'nippon@bitrialsupport.com', 'phone': '05050508862'}], 'facility': 'Japanese Foundation for Cancer Research'}, {'zip': '13496', 'city': 'Seongnam-si', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'CHA Bundang Medical Center', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '13620', 'city': 'Seongnam-si', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Seoul National University Bundang Hospital', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '03722', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '2841', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Korea University Anam Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '3080', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '6273', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': "The Catholic University of Korea, Seoul St.Mary's Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '6591', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'namhan@bitrialsupport.com', 'phone': '0808802084'}], 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '15006', 'city': 'A Coruña', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Teresa Herrera', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '08003', 'city': 'Barcelona', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital del Mar', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Universitari Vall D Hebron', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Clínic de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '8906', 'city': "L'Hospitalet de Llobregat", 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Duran i Reynals', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '28007', 'city': 'Madrid', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital General Universitario Gregorio Marañón', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28022', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Clínica Universidad de Navarra - Madrid', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Fundación Jiménez Díaz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Clínico San Carlos', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Universitario 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Universitario La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28050', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'CIO Clara Campal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41009', 'city': 'Seville', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Hospital Universitario Virgen De La Macarena', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46009', 'city': 'Valencia', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'espana@bitrialsupport.com', 'phone': '900876092'}], 'facility': 'Instituto Valenciano de Oncología', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': 'CF14 2TL', 'city': 'Cardiff', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': 'Velindre Cancer Centre', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'LS9 7TF', 'city': 'Leeds', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': "St James's University Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'EC1A 7BE', 'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': "St Bartholomew's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NW1 2PG', 'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': 'University College Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NW3 2QG', 'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': 'Royal Free Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': 'The Christie', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'NG5 1PB', 'city': 'Nottingham', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'unitedkingdom@bitrialsupport.com', 'phone': '08000514022'}], 'facility': 'Nottingham University Hospitals NHS Trust', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}], 'centralContacts': [{'name': 'Boehringer Ingelheim', 'role': 'CONTACT', 'email': 'clintriage.rdg@boehringer-ingelheim.com', 'phone': '1-800-243-0127'}]}, 'ipdSharingStatementModule': {'url': 'https://www.mystudywindow.com/msw/datasharing', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.', 'ipdSharing': 'YES', 'description': 'Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".\n\nFurthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.', 'accessCriteria': "For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}